Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Boolean network-based identification of optimal drug combinations for prostate cancer.

Computational biology and chemistry·2026

Same author

Targeting colorectal cancer liver metastasis through repurposing metabolic and immune inhibitors: A theoretical study.

Computational biology and chemistry·2025

Same author

Performance of a first-trimester combined screening for preterm preeclampsia in the United States population using the fetal medicine foundation competing risks model.

American journal of obstetrics & gynecology MFM·2025

Same author

Modulation of COVID-19 incidence by environmental stressors is variant between pre-Omicron and Omicron periods.

Scientific reports·2025

Same author

Proliferation symmetry breaking in growing tissues.

bioRxiv : the preprint server for biology·2024

Same author

Pathway-based analyses of gene expression profiles at low doses of ionizing radiation.

Frontiers in bioinformatics·2024

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Cancer therapy design based on pathway logic.

Ritwik Layek¹, Aniruddha Datta, Michael Bittner

¹Department of Electrical and Computer Engineering, Texas A & M University, College Station, TX 77843-3128, USA.

Bioinformatics (Oxford, England)

|January 4, 2011

Summary

This study models cancer cell signaling pathways using Boolean logic to identify specific malfunctions. This approach helps determine the most effective drug combinations for targeted cancer therapy.

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Area of Science:

Oncology
Systems Biology
Computational Biology

Background:

Cancer is characterized by uncontrolled cell proliferation due to cell cycle deregulation.
Cellular signaling pathway malfunctions are primary drivers of cancer development.
Effective cancer therapy requires precise identification of malfunction location and type for optimal drug combinations.

Purpose of the Study:

To model growth factor (GF) signaling pathways in cancer using Boolean logic.
To systematically identify and classify all possible single malfunctions within these pathways.
To map specific malfunctions to effective drug combinations for targeted cancer treatment.

Main Methods:

Utilized Boolean logic gates to model interactions within GF signaling pathways.
Enumerated all potential single component malfunctions in the Boolean circuit model.
Analyzed the response of malfunctioning circuits to test inputs to classify malfunction types.
Integrated drug effects targeting specific Boolean circuit components to assess efficacy.

Main Results:

Developed a Boolean model for GF signaling pathways relevant to cancer.
Classified various single malfunctions based on their circuit response patterns.
Demonstrated a method to map identified malfunctions to appropriate drug combinations.
Provided a framework for personalized cancer therapy based on pathway analysis.

Conclusions:

Boolean modeling offers a robust method for dissecting cancer signaling pathway dysfunctions.
Understanding malfunction classes is crucial for selecting effective combination therapies.
This approach facilitates the rational design of targeted cancer treatments by matching drugs to specific pathway defects.